GlaxoSmithKline PLC (GSK): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

GlaxoSmithKline ( GSK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, GlaxoSmithKline rose $0.62 (1.2%) to $50.84 on average volume. Throughout the day, 2,724,441 shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2,107,500 shares. The stock ranged in a price between $50.67-$50.95 after having opened the day at $50.82 as compared to the previous trading day's close of $50.22. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 132.5%, Idera Pharmaceuticals ( IDRA), up 24.4%, Omeros Corporation ( OMER), up 18.2% and Oncolytics Biotech ( ONCY), up 16.8%.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.1 billion and is part of the health care sector. Shares are up 17.7% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 33.1%, Delcath Systems ( DCTH), down 11.9%, Zalicus ( ZLCS), down 11.7% and DARA Biosciences ( DARA), down 10.8% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.